tokens: The aim of this study was ; 1 ) To explore alterations in the TP53 gene with respect to resistance to a regular dose epirubicin regimen ( 90 mg / m2 every 3 week ) in patients with primary , locally advanced breast cancer ; 2 ) Identify critical mechanisms activating p53 in response to DNA damage in breast cancer ; 3 ) Evaluate in vitro function of Chk2 and p14 proteins corresponding to identified mutations in the CHEK2 and p14 ( ARF ) genes ; and 4 ) Explore potential CHEK2 or p14 ( ARF ) germline mutations with respect to family cancer incidence .